Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14051608 | 0.82 | CYP1A2 (0.39) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL29331537 | 0.78 | ALDH1A1 (0.35) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL16136624 | 0.78 | TRPV4 (0.37) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL422454 | 0.78 | EPAS1 (0.39) | EPAS1TRPV4 | |
| SCHEMBL12326880 | 0.76 | MAPT (0.41) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL406265 | 0.75 | KDM4E (0.37) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL16545829 | 0.75 | HSD17B10 (0.41) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL423158 | 0.75 | AR (0.37) | EPAS1KDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL16680976 | 0.75 | LMNA (0.34) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL16936527 | 0.75 | EPAS1 (0.40) | EPAS1KDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112351-B1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-9914707-B2 | Naphthylamide compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-03-13 | — | — | US | disclosed |
| US-20170066723-A1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3112351-A1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-01-04 | — | — | EP | disclosed |
| US-8940778-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8642776-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8299243-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2246333-B1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-1638941-B1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LAB (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-7598283-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| US-7297709-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-11-20 | — | — | US | disclosed |
| CN-1826324-A | Indazole, benzisoxazole and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2006-08-30 | — | — | CN | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABBOTT LABORATORIES | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | EPAS1 2273/4885KDM4E 898/4885HSD17B10 3054/4885 |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | EPAS1 2273/4885KDM4E 898/4885HSD17B10 3054/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | EPAS1 2273/4885KDM4E 898/4885HSD17B10 3054/4885 |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABL1, MAP3K19, MAP3K1 | EPAS1 1628/4885KDM4E 924/4885HSD17B10 2812/4885 |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | EPAS1 2273/4885KDM4E 898/4885HSD17B10 3054/4885 |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | EPAS1 2273/4885KDM4E 898/4885HSD17B10 3054/4885 |
| US-20170066723-A1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | KDR, FLT1, FLT4 | EPAS1 312/4885KDM4E 2807/4885HSD17B10 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.